Biodexa Pharmaceuticals (BDRX) director Simon Turton reports initial equity holdings

Rhea-AI Filing Summary

Biodexa Pharmaceuticals director Simon Turton has filed an initial ownership report for company securities. The filing shows a stock option over 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The option vests over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to continued service. Turton also reports direct ownership of 2,765 Ordinary Shares. Each American Depositary Share represents 100,000 Ordinary Shares of Biodexa Pharmaceuticals.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Turton Simon

(Last) (First) (Middle)

C/O BIODEXA PHARMACEUTICALS PLC

1 CASPIAN POINT, CASPIAN WAY

(Street)

CARDIFF CF104DQ

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Biodexa Pharmaceuticals Plc [ BDRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	2,765	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/23/2034	American Depositary Shares(2)	288	$475(3)	D

Explanation of Responses:

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

3. The exercise price for this option is denominated in British pounds sterling at a price of GBP 373.936 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2703. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney

	/s/ Fiona Mary Powell, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Biodexa (BDRX) director Simon Turton report on his Form 3?

Simon Turton reported his initial ownership in Biodexa on Form 3. He holds a stock option over 288 American Depositary Shares and directly owns 2,765 Ordinary Shares, establishing his starting equity position as a company director.

How many Biodexa American Depositary Shares are covered by Simon Turton’s option?

The option reported by Simon Turton covers 288 American Depositary Shares. These ADSs are a derivative security, giving him the right to buy shares at a fixed exercise price by a set expiration date in 2034, subject to vesting.

What is the exercise price and term of Simon Turton’s Biodexa stock option?

Turton’s stock option has an exercise price of $475.0000 per American Depositary Share and expires on January 23, 2034. The price is originally denominated in British pounds and was converted into U.S. dollars using a stated exchange rate.

How do Biodexa American Depositary Shares relate to Ordinary Shares?

Each Biodexa American Depositary Share represents 100,000 Ordinary Shares. This ratio means the ADS is a bundled form of the company’s Ordinary Shares, allowing trading in U.S. markets while still reflecting underlying Ordinary Share ownership.

How do Simon Turton’s Biodexa stock options vest over time?

The option vests over four years. Twenty-five percent of the underlying shares vest on the one-year anniversary of the grant, and 6.25% vest every three months thereafter, provided Turton continues to serve through each applicable vesting date.

How many Biodexa Ordinary Shares does Simon Turton directly own?

Simon Turton directly owns 2,765 Ordinary Shares of Biodexa. This direct shareholding is separate from his stock option over American Depositary Shares and reflects his current beneficial ownership in the company’s underlying equity.